Major gaps exist in patient understanding of genomic test results, Lung-MAP study shows
A majority of cancer patients don’t understand key aspects of the genomic test results they receive as participants in biomarker-driven clinical trials, according to a first-of-its-kind pilot study conducted under the Lung Cancer Master Protocol (Lung-MAP). In a September 9 presentation at the World Conference on Lung Cancer in Barcelona, Lung-MAP investigator Joshua A. Roth, PhD,…
Lung-MAP Precision Medicine Trial Expands To Include More Patients
For Immediate Release Jan. 29, 2019 Please Contact: Ryan Hohman, Vice President – Public Affairs, Friends of Cancer Research rhohman@focr.org; 202-944-6708 Wendy Lawton, Communications Manager, SWOG lawtonw@ohsu.edu; 503.348.8675 Lung-MAP Precision Medicine Trial Expands To Include More Patients Washington, DC – The Lung Cancer Master Protocol (Lung-MAP), the first precision medicine trial in lung cancer supported by the…